InsiderTrades.com logo
J.P. Morgan’s DIRE Warning
From Behind the Markets   |   Ad
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
Click here to see why Wall Street is in PANIC mode >>>

NKGN Insider Trading

Insider Ownership Percentage: 20.00%
Insider Buying (Last 12 Months): $1,261.12
Insider Selling (Last 12 Months): $0.00

NKGen Biotech Insider Trading History Chart

This chart shows the insider buying and selling history at NKGen Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NKGen Biotech Share Price & Price History

Current Price: $1.20
Price Change: ▲ Price Increase of +0.05 (4.35%)
As of 07/26/2024 01:00 AM ET

This chart shows the closing price history over time for NKGN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
“Generational Bull Run” Incoming
From Unstoppable Prosperity   |   Ad
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
You can find out what they are by clicking here now.

NKGen Biotech Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/6/2023Paul Y SongCEOBuy75$3.32$249.00171,045View SEC Filing Icon  
11/27/2023Paul Y SongCEOBuy244$2.88$702.72170,701View SEC Filing Icon  
11/21/2023Paul Y SongCEOBuy100$2.80$280.00170,405View SEC Filing Icon  
11/20/2023James A GrafCFOBuy10$2.94$29.4010View SEC Filing Icon  
See Full Table
“Generational Bull Run” Incoming
From Unstoppable Prosperity   |   Ad
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
You can find out what they are by clicking here now.

SEC Filings (Institutional Ownership Changes) for NKGen Biotech (NYSE:NKGN)

76.17% of NKGen Biotech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

NKGen Biotech Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/1/2024Sequoia Financial Advisors LLC16,000$30K0.0%N/A0.070%Search for SEC Filing on Google Icon
3/14/2024University of Chicago550,000$1.51M2.1%N/A2.513%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
NKGen Biotech logo
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
Read More on NKGen Biotech

Today's Range

Now: $1.20
Low: $1.12
High: $1.23

50 Day Range

MA: $1.32
Low: $0.90
High: $1.86

52 Week Range

Now: $1.20
Low: $0.78
High: $12.88

Volume

269,957 shs

Average Volume

2,203,660 shs

Market Capitalization

$30.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Who are the company insiders with the largest holdings of NKGen Biotech?

NKGen Biotech's top insider shareholders include:
  1. Paul Y Song (CEO)
  2. James A Graf (CFO)
Learn More about top insider investors at NKGen Biotech.
J.P. Morgan’s DIRE Warning
From Behind the Markets   |   Ad
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
Click here to see why Wall Street is in PANIC mode >>>